
Topic
Orange Book
Patent/exclusivity records, therapeutic-equivalence codes, reference-listed drugs, and ANDA planning.

Generics· June 25, 2026 · 19 min read
By Ran Chen#Generics#Orange Book#FDA Approval

Generics· June 25, 2026 · 19 min read
Generic Forteo: Drug-Device Pathways and PBM Exclusions
By Ran Chen#Generics#Orange Book#505(b)(2)

Generics· June 25, 2026 · 19 min read
Generic Gilenya: Dosing Patent Expiry and 99% Price Erosion
By Ran Chen#Generics#Orange Book#PBM

Pricing & Access· June 24, 2026 · 25 min read
Eli Lilly Portfolio Dossier: Diabetes, Obesity, and Insulin Pricing

Pricing & Access· June 24, 2026 · 26 min read
J&J Janssen Portfolio Dossier: Stelara Biosimilars and Oncology Assets
By Ran Chen#Purple Book#Orange Book#Biosimilars

Pricing & Access· June 24, 2026 · 25 min read
Novartis Portfolio Dossier: Spinoff Splits and Patent Cliffs
By Ran Chen#Orange Book#Purple Book#Generics

Pricing & Access· June 24, 2026 · 26 min read
Pfizer Portfolio Dossier: Patent Cliffs, Shortages, and Recalls
By Ran Chen#Orange Book#Purple Book#FDA Approval

Generics· June 24, 2026 · 18 min read
When is Generic Imbruvica Available? The 522-Patent Wall and Litigation Settlement Reality
By Ran Chen#Orange Book#Generics#Generic Entry

Generics· June 23, 2026 · 17 min read
Eliquis Generic: Why US Entry is Delayed to April 2028 Despite IRA Cuts
By Ran Chen#Generic Entry#FDA Approval#Orange Book

Generics· June 23, 2026 · 17 min read
When is Generic Ozempic Available? The US Semaglutide Patent-Cliff Reality
By Ran Chen#Generic Entry#FDA Approval#Orange Book